Lactose Market

How Big is the Lactose Market in 2026?

Lactose market size is estimated at USD 2.3 Billion in 2026, up from USD 2.2 Billion in 2025. Sales of lactose will record a 4.1% CAGR over the next decade. As per FMI’s analysis, the lactose market valuation will reach USD 3.4 Billion by 2036.

The demand for lactose in food and beverages, pharmaceuticals, animal feed, and emerging high-purity derivatives. Demand for formulators is increasing owing to its multifaceted use as a filler, binder, and carrier. The updated report by FMI finds that steady use of pharmaceutical lactose in tablets, capsules, and inhaled products keeps volume stable.

The demand in Asia Pacific is growing due to high-volume use in food manufacturing, industrial-scale buying and repeat orders. The USA is forecasted to grow at a steady pace, supported by demand from both food and pharmaceutical buyers. US buyers place strong weight on proven supplier performance and consistent excipient quality.

In Europe, purchasing is quality-led and regulated, so buyers focus on consistent inputs. The UK gains from structured procurement and repeat buying in regulated food and pharma sectors. Growth in Latin America, the Middle East and Africa is slower, but expansion of the food and beverage industry in these regions is expected to support demand.

Growth of lactose sales across these five markets, and across the other 30+ countries in the report, is set to come from grades that clear buyer qualification and ship with complete documentation.

Key Takeaways

• Key trends in the lactose market include standard lactose grades that come with carbon data and low nitrite levels.
• Germany is set to record the fastest growth among profiled countries, at a 5.2% CAGR till 2036. The UK trails at 3% CAGR through 2036.
• Powder is the preferred format as it suits bulk handling and standard formulation workflows. Lactose powder is set to hold 93.4% of the form category in 2026.
• A few of the notable companies are DFE Pharma, MEGGLE, Lactalis Ingredients, Hilmar Ingredients, Leprino Foods, Arla Foods Ingredients, Kerry, and Fresenius Kabi, out of many players covered in the full report.
• Prescription use as a laxative and in hepatic encephalopathy care keeps demand for lactulose steady. As a result, lactulose accounts for 28.3% of derivatives type revenue in 2026.

Analyst Perspective

“As per my analysis, investments in pharmaceutical-grade lactose will bring most ROI to drug makers. On supply side, focus should be on purity grades and low nitrite and carbon data.”

- Nandini Roy Choudhury, Principal Consultant, Future Market Insights

How is the Lactose Market Segmented?

The lactose market is segmented by Form, Derivatives Type, End Use, and Region.

Lactose market report, by form, has been segmented into powder and granule. Derivatives type covers lactulose, lactose monohydrate, lactose anhydrous, galactose, lactitol, and other derivatives such as tagatose and lactobionic acid. Based on end use, FMI report covers pharmaceutical, food and beverage, bakery, animal feed, confectionery, cosmetics and personal care, and functional food. Regional coverage extends to seven regions and 30+ countries.

What Makes Powder Central to the Form Category?

Lactose powder will capture 93.4% market share in 2026.

The demand for lactose powder is growing as it blends, measures and dissolves easily across food, pharmaceutical and infant formula production. Adoption of pharmaceutical-grade lactose powder is high among drug makers, as its uniform particle size gives accurate dosing in tablets, capsules and dry-powder inhalers. Key trends in the lactose market include low-cost production from whey by-products and easy bulk supply.

• Demand for refined lactose powder will keep rising across dry mixes in food and feed.
• Demand for lactose powder will be 93.4% of the form category in 2026.
• Azelis agreed in June 2026 to distribute the Lactalpha range from Lactalis in India. The range includes milled and sieved low-nitrite lactose for wet and dry granulation.

Why Does Lactulose Lead the Derivatives Type Category?

Lactulose will account for 28.3% market share, among other derivatives in 2026.

According to the FMI’s report, demand for lactulose will remain dominant owing to its use as probiotic in functional food. Lactose producers are also monetizing and tapping into consumer demand for gut health products and supplements to capture more sales opportunities.

Through 2026, sales of lactulose will rise as doctors prescribe it for chronic constipation and hepatic encephalopathy. As a result, steady sales are expected from pharmaceutical segment.

• A DailyMed label update in July 2026 listed lactulose oral solution at 10 g per 15 ml. The label described the solution as a colonic acidifier that promotes laxation.
• Market share of lactulose is expected to grow to 28.3% in 2026.

What Supports Demand for Pharmaceutical in the End Use Category?

Trade partnerships with pharmaceutical industry players will attract more sales opportunities through 2036. A market share of 33.9% in 2026 is estimated for sales from pharmaceutical industry.

A significant share to the overall revenue opportunity bucket will come from pharmaceutical industry during the forecast period. Demand from oral solid dosage and dry powder inhalation will continue to anchor pharmaceutical end use.

• Besides this, food and beverage will remain a large outlet with lighter qualification.
• Sales of lactose to pharmaceutical buyers will be 33.9% of end use revenue in 2026.
• Bakery and confectionery demand will stay tied to browning and solids performance.

What Are the Drivers, Restraints, and Opportunities in the Lactose Market?

Key drivers of the lactose market center on pharmaceutical formulation demand for qualified grades. Impurity-control rules will keep raising switching costs. Specialty grades and derivatives will open a path to higher-value supply till 2036.

• Driver: Drug formulators will keep rewarding compendial lactose for its consistent supply and controlled physical properties.
• Restraint: Nitrite, microbial, and change-control checks will keep stretching qualification cycles and raising the cost of supplier switching.
• Opportunity: Investments in low-nitrite, inhalation, and low-carbon grades will bring suppliers the most ROI above standard lactose pricing.

Demand for food-grade lactose will keep growing in infant formula and functional foods across Asia Pacific and Latin America. Adoption of lactose will rise as its carbohydrate content matches human breast milk, keeping it the preferred base in cow's milk-based infant formulas. Prebiotic derivatives such as GOS will keep opening higher-value demand segments in premium infant nutrition formulas.

Sales of a new lactose grade will keep entering medicines slowly, since each change needs review. Reformulation work will keep placing every excipient under closer scrutiny. Consumer lactose intolerance will keep pushing some food uses toward lactase and lactose-free products.

Which country CAGRs are profiled in the lactose market?

Country	CAGR, 2026 to 2036
Germany	5.2%
USA	4.3%
South Korea	3.9%
Japan	3.5%
UK	3.0%

How do country-level CAGRs compare?

The five profiled countries span a 2.2-percentage-point range through 2036, as per FMI. Germany leads at 5.2%, followed by the USA at 4.3%, South Korea at 3.9%, Japan at 3.5%, and the UK at 3.0%. These figures track growth pace, not market size.

• Germany's 0.9-point lead over the USA rests on EU policy support for local pharmaceutical production and supply security.
• The 0.4-point gap between the USA and South Korea comes down to qualification speed and distributor access.
• South Korea holds a 0.4-point lead over Japan.
• Japan sits 0.5 points above the UK.

The full report covers country-level CAGR analysis to over 30 countries across North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and the Middle East and Africa.

Country Outlook

• Demand for lactose in Germany will grow at a 5.2% CAGR till 2036, the fastest pace among profiled countries. Germany and France signed a joint declaration in May 2026 to incentivise EU-based pharmaceutical production. The declaration also aims to strengthen security of supply. Key challenges in the German lactose market include high regulatory and manufacturing costs.
• Sales of lactose in the USA will grow at a 4.3% CAGR from 2026 to 2036. Nitrosamine controls shape buying. Formulation teams purchase against compendial specifications. Impurity risk is reviewed at supplier level. The FDA gave drug makers the option in June 2025 to file progress reports on nitrosamine mitigation.
• Adoption of multi-compendial lactose grades in South Korea will rise with export-focused drug making. Lactose demand in the country will grow at a 3.9% CAGR over the forecast period. The government announced a plan in September 2025 to cut drug review periods by about four months.
• The lactose market in Japan will grow at a 3.5% CAGR till 2036. Approvals run through a formal system under the PMD Act. The PMDA published an updated translation of manufacturing and marketing procedures for drugs in August 2025. The document covers accreditation of foreign production sites.
• The UK lactose market will rise at a 3.0% CAGR through 2026. The UK government announced more than £80 million of life sciences investment in April 2026. Accord committed over £45 million of the total at the company's Barnstaple site. The Life Sciences Innovative Manufacturing Fund backed these projects.

Who are the notable companies in the lactose market?

Key companies operating in the lactose market are DFE Pharma, MEGGLE, Lactalis Ingredients, Hilmar Ingredients, Leprino Foods, Arla Foods Ingredients, Kerry, and Fresenius Kabi.

Dairy groups purify lactose from in-house whey permeate streams. Pharmaceutical specialists refine the milk sugar into excipient grades. 

• Pharmaceutical Lactose Excipient Specialists: DFE Pharma, MEGGLE, and Lactalis Ingredients supply compendial lactose for tablets, capsules, and inhalation.
• Dairy Processors with Food and Nutrition Lactose: Hilmar Ingredients, Leprino Foods, and Arla Foods Ingredients produce edible lactose from cheese and whey operations. The group also offers dairy ingredients such as demineralized whey for infant and nutrition uses.
• Diversified Ingredient and Derivative Suppliers: Kerry and Fresenius Kabi compete on breadth. Kerry sells Sheffield pharmaceutical lactose.

Competitive Benchmarking

Company	Pharmaceutical-Grade Qualification	Derivative Processing	End-Use Breadth	Geographic Reach
DFE Pharma	High	Low	Medium	Europe, Americas, and Asia, with an application center in India
MEGGLE	High	Low	Medium	Europe, Americas, and Asia
Lactalis Ingredients	High	Low	High	Europe with global distribution, including India
Hilmar Ingredients	Low	Low	Medium	North America with global exports
Leprino Foods	Low	Low	Medium	North America with global exports
Arla Foods Ingredients	Low	Low	Medium	Europe with global customers
Kerry	High	Low	High	Global, with US pharmaceutical distribution
Fresenius Kabi	High	High	Medium	Global, supplied from Austria

Scoring basis: Pharmaceutical-Grade Qualification measures documented compendial lactose or lactose-derived active ingredients made for drug use. Derivative Processing measures documented production of lactulose or other listed derivatives. End-Use Breadth measures documented supply across pharmaceutical, food, nutrition, and feed uses. High indicates broad, clearly documented capability. Medium indicates credible but narrower capability. Low indicates limited public documentation for the criterion. Geographic Reach reflects evidenced sales, distribution, or facility activity. The scoring rests on public company records reviewed in September 2026.

Key Developments

• In February 2026, DFE Pharma introduced EcoLact 2030. The program offers a data-verified 30% CO₂ reduction across the company’s lactose portfolio with no change in product quality or performance.
• In June 2026, Azelis announced a partnership with Lactalis to distribute the Lactalpha pharmaceutical lactose range across India.

Key Players

Pharmaceutical Lactose Excipient Specialists

• DFE Pharma
• MEGGLE
• Lactalis Ingredients

Dairy Processors with Food and Nutrition Lactose

• Hilmar Ingredients
• Leprino Foods
• Arla Foods Ingredients

Diversified Ingredient and Derivative Suppliers

• Kerry
• Fresenius Kabi

Report Scope and Methodology

Coverage field	Report scope
Market breakdown	Four categories, namely Form (Powder, Granule), Derivatives Type (Lactulose, Lactose Monohydrate, Lactose Anhydrous, Galactose, Lactitol, Other), End Use (Pharmaceutical, Food and Beverage, Bakery, Animal Feed, Confectionery, Cosmetics and Personal Care, Functional Food), and Region
Quantitative units	USD Billion
Market definition	Revenue from lactose and the listed lactose derivatives sold as ingredients or pharmaceutical excipients within the stated form and end-use categories. The definition excludes finished drugs, finished foods and beverages, lactase enzymes, lactose-free products, whey powders, milk powders, and adjacent substitutes.
Regions covered	North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries covered	30+ countries, including the USA, the UK, Germany, Japan, and South Korea
Key companies profiled	DFE Pharma, MEGGLE, Lactalis Ingredients, Hilmar Ingredients, Leprino Foods, Arla Foods Ingredients, Kerry, and Fresenius Kabi, a few of the notable companies out of many players covered by FMI
Forecast period	2026 to 2036
Approach	FMI applies a hybrid bottom-up and top-down sizing framework that reconciles supplier-side activity with application demand and country conditions, with checks against the market boundary.

Research Methodology

Method	Approach
Primary research	FMI’s primary-research framework engages lactose manufacturers, derivative processors, distributors, pharmaceutical formulators, procurement specialists and end-use buyers to test purchasing criteria, grade qualification, pricing logic and supply constraints.
Desk research	The analysis reviews pharmacopoeial standards, regulator guidance, national policy documents, company newsrooms and technical product documentation. FMI retains sources that support the market boundary or a specific operating mechanism.
Market sizing and forecasting	Market values are reconciled with product form, derivative mix, end-use demand, supplier qualification, country manufacturing conditions and supply availability. Forecasts consider specialty-grade adoption, regulatory burden and the pace at which qualified supply turns into recurring purchases.
Data validation	Cross-checks test numerical consistency, scope alignment and country-rate consistency. Finished-product revenue, adjacent substitutes, duplicate value capture and out-of-scope products are excluded before final reconciliation.

Lactose Market by Segments

Lactose Market Segmented by Form

• Powder
• Granule

Lactose Market Segmented by Derivatives Type

• Lactulose
• Lactose Monohydrate
• Lactose Anhydrous
• Galactose
• Lactitol
• Other (tagatose, lactobionic acid)

Lactose Market Segmented by End Use

• Pharmaceutical
• Food and Beverage
• Bakery
• Animal Feed
• Confectionery
• Cosmetics and Personal Care
• Functional Food

Lactose Market Segmented by Region

• North America
• Latin America
• Western Europe
• Eastern Europe
• East Asia
• South Asia and Pacific
• Middle East and Africa

Research Sources and Bibliography

• Sidley Austin LLP (2025, June 23). U.S. FDA Revises Deadline for Submitting Changes to Mitigate Nitrosamine Impurities in Drugs.
• DailyMed (2026, July 24). Lactulose Solution Drug Label.
• Pharmaceuticals and Medical Devices Agency (2026, September 11). Implementation of PDG harmonized texts into Japanese Pharmacopoeia (Monographs).
• Pharmaceuticals and Medical Devices Agency (2025, August). Manufacturing and Marketing Procedures for Drugs.
• Korea Biomedical Review (2025, September 8). Korea fast-tracks biopharma push with 2030 global top-5 goal.
• UK Government (2026, April 14). Vital medicines and new jobs in over £80 million for UK life sciences.
• Federal Ministry of Health, Germany (2026, May 19). Germany and France Sign Joint Declaration on Strengthening the Pharmaceutical Industry in Europe.
• DFE Pharma (2026, February 4). DFE Pharma introduces EcoLact 2030, delivering a data-verified CO₂ reduction across its lactose portfolio.
• DFE Pharma (2026, February 17). DFE Pharma launches Continuous Manufacturing platform to accelerate and enable formulation development.
• DFE Pharma (2026, June 10). DFE Pharma earns third consecutive EcoVadis Gold Medal for sustainability performance.
• Azelis (2026, June 2). Azelis expands pharmaceutical excipient portfolio in India through Lactalis partnership.

This bibliography serves as a reader reference and is not exhaustive. The full report holds the complete reference list and detailed citations.

This Report Answers

• What is the Lactose Market size in 2026?
• What CAGR is forecast for Lactose Market during 2026-2036?
• Which segments hold notable 2026 shares in Lactose Market?
• Which countries show notable Lactose Market growth over 2026-2036?
• Which companies participate in the Lactose Market today?
• What scope defines the Lactose Market boundary today?